AR036663A1 - Compuestos de espiro-hidantoina utiles como agentes anti-inflamatorios, las composiciones farmaceuticas que las contienen y los intermediarios para preparar dichos compuestos - Google Patents
Compuestos de espiro-hidantoina utiles como agentes anti-inflamatorios, las composiciones farmaceuticas que las contienen y los intermediarios para preparar dichos compuestosInfo
- Publication number
- AR036663A1 AR036663A1 ARP020103695A ARP020103695A AR036663A1 AR 036663 A1 AR036663 A1 AR 036663A1 AR P020103695 A ARP020103695 A AR P020103695A AR P020103695 A ARP020103695 A AR P020103695A AR 036663 A1 AR036663 A1 AR 036663A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- alkyl
- ring
- heteroaryl
- cycloalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 229940121363 anti-inflammatory agent Drugs 0.000 title abstract 2
- 239000002260 anti-inflammatory agent Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 9
- 125000000623 heterocyclic group Chemical group 0.000 abstract 9
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000003118 aryl group Chemical group 0.000 abstract 7
- -1 Spiro-hydantoin compound Chemical class 0.000 abstract 5
- 125000002947 alkylene group Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 5
- 125000002252 acyl group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 4
- 125000004414 alkyl thio group Chemical group 0.000 abstract 4
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 4
- 125000005864 sulfonamidyl group Chemical group 0.000 abstract 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 4
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000004474 heteroalkylene group Chemical group 0.000 abstract 3
- 125000005017 substituted alkenyl group Chemical group 0.000 abstract 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 102100022339 Integrin alpha-L Human genes 0.000 abstract 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000000468 ketone group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32636101P | 2001-10-01 | 2001-10-01 | |
| US35411302P | 2002-02-04 | 2002-02-04 | |
| US40025902P | 2002-08-01 | 2002-08-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036663A1 true AR036663A1 (es) | 2004-09-22 |
Family
ID=27406458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020103695A AR036663A1 (es) | 2001-10-01 | 2002-09-30 | Compuestos de espiro-hidantoina utiles como agentes anti-inflamatorios, las composiciones farmaceuticas que las contienen y los intermediarios para preparar dichos compuestos |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US6977267B2 (enExample) |
| EP (1) | EP1432700B1 (enExample) |
| JP (1) | JP4394442B2 (enExample) |
| KR (1) | KR20040041649A (enExample) |
| CN (1) | CN1596253A (enExample) |
| AR (1) | AR036663A1 (enExample) |
| AT (1) | ATE447565T1 (enExample) |
| BR (1) | BR0213025A (enExample) |
| CA (1) | CA2462112A1 (enExample) |
| DE (1) | DE60234264D1 (enExample) |
| ES (1) | ES2339107T3 (enExample) |
| GE (1) | GEP20063767B (enExample) |
| HR (1) | HRP20040311A2 (enExample) |
| HU (1) | HUP0402338A3 (enExample) |
| IL (1) | IL160990A0 (enExample) |
| IS (1) | IS7197A (enExample) |
| MX (1) | MXPA04002993A (enExample) |
| NO (1) | NO20041339L (enExample) |
| NZ (1) | NZ531870A (enExample) |
| PE (1) | PE20030845A1 (enExample) |
| PL (1) | PL369337A1 (enExample) |
| RS (1) | RS26604A (enExample) |
| WO (1) | WO2003029245A1 (enExample) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040242568A1 (en) * | 2003-03-25 | 2004-12-02 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
| DE602004027171D1 (de) * | 2003-04-11 | 2010-06-24 | High Point Pharmaceuticals Llc | Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase |
| US7700583B2 (en) | 2003-04-11 | 2010-04-20 | High Point Pharmaceuticals, Llc | 11β-hydroxysteroid dehydrogenase type 1 active compounds |
| JP2007511467A (ja) | 2003-05-14 | 2007-05-10 | タケダ サン ディエゴ インコーポレイテッド | ジペプチジルペプチダーゼインヒビター |
| MXPA06001601A (es) * | 2003-08-13 | 2006-08-25 | Takeda Pharmaceutical | Derivados de 4-pirimidona y su uso como inhibidores de dipeptidilpeptidasa. |
| US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| WO2005026148A1 (en) * | 2003-09-08 | 2005-03-24 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| US20050065144A1 (en) * | 2003-09-08 | 2005-03-24 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
| US7199125B2 (en) | 2003-10-02 | 2007-04-03 | Bristol-Myers Squibb Company | Spiro-cyclic compounds useful as anti-inflammatory agents |
| AU2004287875B2 (en) | 2003-11-05 | 2011-06-02 | Bausch + Lomb Ireland Limited | Modulators of cellular adhesion |
| EP2299266A1 (en) | 2003-12-19 | 2011-03-23 | The Regents of the University of California | Methods and materials for assessing prostate cancer therapies |
| NZ550102A (en) | 2004-02-24 | 2010-10-29 | Univ California | Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives) |
| US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| CN102079743B (zh) * | 2004-03-15 | 2020-08-25 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
| US7687638B2 (en) * | 2004-06-04 | 2010-03-30 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| DK2433943T3 (da) | 2004-07-01 | 2013-12-16 | Daiichi Sankyo Co Ltd | Mellemprodukter til thienopyrazol-derivater med PDE7-inhibitorisk aktivitet |
| WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| US7375237B2 (en) | 2004-08-18 | 2008-05-20 | Bristol-Myers Squibb Company | Pyrrolizine compounds useful as anti-inflammatory agents |
| TW200616634A (en) | 2004-10-01 | 2006-06-01 | Bristol Myers Squibb Co | Crystalline forms and process for preparing spiro-hydantoin compounds |
| US8110581B2 (en) | 2004-11-10 | 2012-02-07 | Incyte Corporation | Lactam compounds and their use as pharmaceuticals |
| SG161261A1 (en) | 2004-11-10 | 2010-05-27 | Incyte Corp | Lactam compounds and their use as pharmaceuticals |
| US7186727B2 (en) * | 2004-12-14 | 2007-03-06 | Bristol-Myers Squibb Company | Pyridyl-substituted spiro-hydantoin compounds and use thereof |
| US20060142319A1 (en) * | 2004-12-14 | 2006-06-29 | Bang-Chi Chen | Pyridyl-substituted spiro-hydantoin crystalline forms and process |
| JP2008524331A (ja) * | 2004-12-21 | 2008-07-10 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
| US20080033027A1 (en) * | 2005-03-21 | 2008-02-07 | Vicus Therapeutics Spe 1, Llc | Drug combination pharmaceutical compositions and methods for using them |
| CA2646131C (en) * | 2005-03-21 | 2018-09-04 | Vicus Therapeutics Spe 1, Llc | Compositions and methods for ameliorating cachexia |
| US20090117197A1 (en) * | 2005-03-21 | 2009-05-07 | Vicus Therapeutics Llc | Compositions and methods for ameliorating cachexia |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| JP2009507791A (ja) * | 2005-08-29 | 2009-02-26 | メルク エンド カムパニー インコーポレーテッド | ナイアシン受容体アゴニスト、このような化合物を含有する組成物、および治療方法 |
| NZ566799A (en) * | 2005-09-14 | 2011-04-29 | Takeda Pharmaceutical | Dipeptidyl peptidase inhibitors for treating diabetes |
| GEP20135791B (en) * | 2005-09-14 | 2013-03-25 | Takeda Pharmaceutical | Use of dipeptidyl peptidase inhibitors |
| WO2007035629A2 (en) * | 2005-09-16 | 2007-03-29 | Takeda Pharmaceutical Company Limited | Process for the preparation of pyrimidinedione derivatives |
| TW200745080A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor |
| TW200745079A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor |
| CN101304976A (zh) * | 2005-10-11 | 2008-11-12 | 因特蒙公司 | 病毒复制抑制剂 |
| US8926990B2 (en) | 2009-10-13 | 2015-01-06 | Rutgers, The State University Of New Jersey | Treatment and diagnosis of inflammatory disorders and HIV |
| CN101032483B (zh) * | 2006-03-09 | 2011-05-04 | 陈德桂 | 调节雄激素受体活性的乙内酰脲衍生物及其应用 |
| BRPI0709771B1 (pt) | 2006-03-27 | 2022-01-25 | The Regents Of The University Of California | Composto e composição farmacêutica |
| EP1999108A1 (en) * | 2006-03-28 | 2008-12-10 | Takeda Pharmaceutical Company Limited | Preparation of (r)-3-aminopiperidine dihydrochloride |
| WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| NZ596260A (en) | 2006-03-29 | 2013-05-31 | Univ California | Diarylthiohydantoin compounds |
| US7740064B2 (en) | 2006-05-24 | 2010-06-22 | Baker Hughes Incorporated | System, method, and apparatus for downhole submersible pump having fiber optic communications |
| BRPI0719122A2 (pt) | 2006-08-24 | 2013-12-10 | Novartis Ag | Compostos orgânicos |
| US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
| PL2073810T3 (pl) * | 2006-09-13 | 2012-01-31 | Takeda Pharmaceuticals Co | Zastosowanie 2-6-(3-amino-piperydyn-1-ylo)-3-metylo-2,4-diokso-3,4-dihydro-2H-pirymidyn-1-ylometylo-4-fluoro-benzonitrylu do leczenia cukrzycy, raka, zaburzeń autoimmunizacyjnych i zakażeń HIV |
| MX2009003080A (es) | 2006-09-22 | 2009-04-02 | Novartis Ag | Compuestos organicos heterociclicos. |
| TW200838536A (en) * | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| AU2007336238A1 (en) | 2006-12-20 | 2008-06-26 | Novartis Ag | 2-substituted 5-membered heterocycles as SCD inhibitors |
| US20100093777A1 (en) * | 2007-01-25 | 2010-04-15 | Takeda Pharmaceutical Company Limited | Spiro-ring compound |
| WO2008096746A1 (ja) * | 2007-02-06 | 2008-08-14 | Takeda Pharmaceutical Company Limited | スピロ化合物およびその用途 |
| US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
| WO2009011261A1 (ja) * | 2007-07-19 | 2009-01-22 | Tokuyama Corporation | ヒダントイン環を有する化合物及びその製造方法 |
| CA2702984C (en) | 2007-10-19 | 2017-04-11 | Sarcode Corporation | Compositions and methods for treatment of diabetic retinopathy |
| TWI469971B (zh) | 2007-10-26 | 2015-01-21 | Univ California | 二芳基乙內醯脲類化合物 |
| WO2009061830A1 (en) * | 2007-11-06 | 2009-05-14 | Massachusetts Eye & Ear Infirmary | Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor |
| US8481750B2 (en) | 2009-06-02 | 2013-07-09 | Boehringer Ingelheim International Gmbh | Derivatives of 6,7-dihydro-5H-imidazo[1,2-α]imidazole-3-carboxylic acid amides |
| CN102740699A (zh) | 2009-09-04 | 2012-10-17 | 范德比尔特大学 | 用于治疗神经学上的功能失调的mglur4变构增效剂、组合物和方法 |
| EP3124481B1 (en) | 2010-02-16 | 2018-03-28 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
| KR20150046259A (ko) | 2012-08-23 | 2015-04-29 | 앨리오스 바이오파마 인크. | 파라믹소바이러스 바이러스성 감염의 치료용 화합물 |
| WO2014052237A1 (en) | 2012-09-26 | 2014-04-03 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| EP2945628B1 (en) | 2013-01-15 | 2020-04-15 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer |
| CA2921294C (en) * | 2013-08-21 | 2023-05-16 | Alios Biopharma, Inc. | Antiviral compounds |
| KR20160133004A (ko) * | 2014-04-04 | 2016-11-21 | 엑스-알엑스, 인크. | 오토탁신의 치환된 스피로시클릭 억제제 |
| CN107108581B (zh) | 2014-08-21 | 2020-06-23 | 百时美施贵宝公司 | 作为强效rock抑制剂的回接苯甲酰胺衍生物 |
| MA41614A (fr) | 2015-02-25 | 2018-01-02 | Alios Biopharma Inc | Composés antiviraux |
| TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
| WO2017170830A1 (ja) * | 2016-03-31 | 2017-10-05 | 武田薬品工業株式会社 | 複素環化合物 |
| KR20240096623A (ko) | 2017-10-16 | 2024-06-26 | 아라곤 파마슈티컬스, 인코포레이티드 | 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐 |
| JP2024502909A (ja) * | 2020-12-24 | 2024-01-23 | アルマルソン、オーン | キサントフィル誘導体 |
| CN115536494B (zh) * | 2022-10-31 | 2023-12-01 | 苏州诚和医药化学有限公司 | 1-(4-溴苯基)-1,4-丁二醇的合成方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1331757C (en) * | 1988-02-29 | 1994-08-30 | Janssen Pharmaceutica Naamloze Vennootschap | 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols |
| US5346913A (en) * | 1992-05-26 | 1994-09-13 | Rohm And Haas Company | N-iodopropargyl hydantoin compounds, compositions, preparation, and use as antimicrobial agents |
| FR2694290B1 (fr) * | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
| TW521073B (en) * | 1994-01-05 | 2003-02-21 | Hoechst Marion Roussel Inc | New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them |
| FR2741342B1 (fr) * | 1995-11-22 | 1998-02-06 | Roussel Uclaf | Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques |
| ATE445400T1 (de) | 2001-05-25 | 2009-10-15 | Bristol Myers Squibb Co | Hydantion-derivate als hemmer von matrix- metalloproteinasen |
-
2002
- 2002-09-30 DE DE60234264T patent/DE60234264D1/de not_active Expired - Lifetime
- 2002-09-30 BR BR0213025-4A patent/BR0213025A/pt not_active IP Right Cessation
- 2002-09-30 NZ NZ531870A patent/NZ531870A/en unknown
- 2002-09-30 CN CNA028238540A patent/CN1596253A/zh active Pending
- 2002-09-30 AR ARP020103695A patent/AR036663A1/es unknown
- 2002-09-30 AT AT02800414T patent/ATE447565T1/de not_active IP Right Cessation
- 2002-09-30 EP EP02800414A patent/EP1432700B1/en not_active Expired - Lifetime
- 2002-09-30 JP JP2003532494A patent/JP4394442B2/ja not_active Expired - Fee Related
- 2002-09-30 KR KR10-2004-7004778A patent/KR20040041649A/ko not_active Withdrawn
- 2002-09-30 RS YU26604A patent/RS26604A/sr unknown
- 2002-09-30 MX MXPA04002993A patent/MXPA04002993A/es unknown
- 2002-09-30 CA CA002462112A patent/CA2462112A1/en not_active Abandoned
- 2002-09-30 PL PL02369337A patent/PL369337A1/xx not_active Application Discontinuation
- 2002-09-30 WO PCT/US2002/031283 patent/WO2003029245A1/en not_active Ceased
- 2002-09-30 HU HU0402338A patent/HUP0402338A3/hu unknown
- 2002-09-30 HR HR20040311A patent/HRP20040311A2/hr not_active Application Discontinuation
- 2002-09-30 ES ES02800414T patent/ES2339107T3/es not_active Expired - Lifetime
- 2002-09-30 IL IL16099002A patent/IL160990A0/xx unknown
- 2002-09-30 GE GE5595A patent/GEP20063767B/en unknown
- 2002-10-01 PE PE2002000971A patent/PE20030845A1/es not_active Application Discontinuation
- 2002-10-01 US US10/262,182 patent/US6977267B2/en not_active Expired - Lifetime
-
2004
- 2004-03-24 IS IS7197A patent/IS7197A/is unknown
- 2004-03-31 NO NO20041339A patent/NO20041339L/no not_active Application Discontinuation
- 2004-05-24 US US10/852,576 patent/US7078420B2/en not_active Expired - Lifetime
- 2004-06-16 US US10/869,292 patent/US20050004153A1/en not_active Abandoned
- 2004-06-16 US US10/869,289 patent/US20040259897A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PE20030845A1 (es) | 2003-10-23 |
| US7078420B2 (en) | 2006-07-18 |
| DE60234264D1 (de) | 2009-12-17 |
| PL369337A1 (en) | 2005-04-18 |
| HUP0402338A2 (hu) | 2005-02-28 |
| MXPA04002993A (es) | 2004-07-15 |
| US6977267B2 (en) | 2005-12-20 |
| US20050004153A1 (en) | 2005-01-06 |
| NZ531870A (en) | 2005-08-26 |
| WO2003029245A1 (en) | 2003-04-10 |
| HK1063467A1 (en) | 2004-12-31 |
| KR20040041649A (ko) | 2004-05-17 |
| HUP0402338A3 (en) | 2008-10-28 |
| IS7197A (is) | 2004-03-24 |
| ES2339107T3 (es) | 2010-05-17 |
| NO20041339L (no) | 2004-05-24 |
| JP4394442B2 (ja) | 2010-01-06 |
| CA2462112A1 (en) | 2003-04-10 |
| HRP20040311A2 (en) | 2005-02-28 |
| US20040259897A1 (en) | 2004-12-23 |
| JP2005510476A (ja) | 2005-04-21 |
| EP1432700B1 (en) | 2009-11-04 |
| ATE447565T1 (de) | 2009-11-15 |
| EP1432700A4 (en) | 2004-12-22 |
| IL160990A0 (en) | 2004-08-31 |
| NO20041339D0 (no) | 2004-03-31 |
| CN1596253A (zh) | 2005-03-16 |
| US20040009998A1 (en) | 2004-01-15 |
| GEP20063767B (en) | 2006-03-10 |
| US20040248920A1 (en) | 2004-12-09 |
| BR0213025A (pt) | 2004-10-05 |
| EP1432700A1 (en) | 2004-06-30 |
| RS26604A (sr) | 2006-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR041184A1 (es) | Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso | |
| AR041009A1 (es) | Compuestos heterociclicos nitrogenados que presentan actividad inhibitoria contra la integrasa del vih | |
| ES2525763T3 (es) | Derivados del ácido fenilalcanoico sustituido y sus usos para el tratamiento de enfermedades respiratorias | |
| AR043199A1 (es) | Componentes heterociclicos utiles para el tratamiento de enfermedades inflamatorias y alergicas, proceso para su operacion y composicion farmaceutica que contiene dichos componentes | |
| AR077267A1 (es) | Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes. | |
| AR036659A1 (es) | Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos | |
| AR033379A1 (es) | Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| CO5660262A2 (es) | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa | |
| ES2328820T3 (es) | Derivados de 4-(pirazol-3-ilamino)pirimidina para uso en el tratamiento de cancer. | |
| AR040336A1 (es) | Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto | |
| AR039226A2 (es) | Compuestos utiles como intermediarios de preparacion y procedimientos | |
| UY26143A1 (es) | Derivados heterocíclicos útiles como agentes anticancerosos | |
| AR036672A1 (es) | Derivados de pirrolidinona | |
| ES2253568T3 (es) | Compuestos heterociclicos para el uso en el tratamiento de los trastornos de las vias urinarias. | |
| AR043875A1 (es) | Derivados de quinazolina, proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| AR020165A1 (es) | Derivados de pirimidinas sustituidas, su procedimiento de preparacion, composiciones farmaceuticas que las contienen y el uso de los mismos para la preparacion de medicamentos | |
| AR009413A1 (es) | Un compuesto, el cual es un derivado de distamicina benzoheterociclico, su utilizacion, un procedimiento para producirlo y una composicionfarmaceutica que lo comprende | |
| AR039927A1 (es) | Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen | |
| AR035945A1 (es) | Derivados de piperacina, su uso en la preparacion de medicamentos, procedimiento para la preparacion de dichos compuestos, composiciones farmaceuticas que comprenden dichos compuestos, y metodo para preparar dichas composiciones | |
| AR045694A1 (es) | Derivados de quinazolina para el tratamiento de enfermedades proliferativas, composiciones farmaceuticas que los contienen y proceso para su preparacion | |
| ATE277897T1 (de) | Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha | |
| AR035317A1 (es) | Derivados de purina, su procedimiento de preparacion, medicamentos, composiciones farmaceuticas y utilizacion de compuestos para la preparacion de medicamentos | |
| AR024494A1 (es) | Proceso para la preparacion de derivados de ciclopentano sustituido y novedosas estructuras cristalinas de los mismos | |
| AR036602A1 (es) | Agonistas muscarinicos | |
| AR041882A1 (es) | Compuestos de imidazopiridina, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |